Big data for HemOnc in Europe: HARMONY

Big data for HemOnc in Europe: HARMONY

VJHemOnc

1 year
117 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
HARMONY is Europe's largest public-private partnership for big data in hematology. Here, Jesús María Hernández Rivas, HARMONY Alliance Project Coordinator, from IBSAL, Spain, discuses the alliance and how big data enable better and faster treatment for patients with hematologic malignancies. This video was recorded at the 23rd congress of the European Hematology Association (EHA) 2018 press briefing, held in Stockholm, Sweden.
Up Next Autoplay
Human Immune Monitoring Center in Mount Sinai to Analyze the Efficacy of a New Drug for Cancer Therapy
Human Immune Monitoring Center in Mount Sinai to Analyze the Efficacy of a New Drug for Cancer Therapy
Category: General
2 Views
Mount Sinai Health System 2 weeks
New Data for BAVENCIO® (avelumab) for Advanced Cancers to Be Presented at ESMO 2019
New Data for BAVENCIO® (avelumab) for Advanced Cancers to Be Presented at ESMO 2019
Category: General
20 Views
Cancer-News 1 month
Interesting Data Presented at WCLC 2019
Interesting Data Presented at WCLC 2019
Category: General
13 Views
Cancer-News 2 months
Calithera Biosciences to Present New Data on Two Oncology Programs at ESMO Congress 2019
Calithera Biosciences to Present New Data on Two Oncology Programs at ESMO Congress 2019
Category: General
20 Views
Cancer-News 2 months
The iQ Group Global acquires new anticancer drug platform from University of Texas
The iQ Group Global acquires new anticancer drug platform from University of Texas
Category: General
12 Views
Cancer-News 2 months
Clinical insights for hematological malignancies from an artificial intelligence decision-support tool.
Clinical insights for hematological malignancies from an artificial intelligence decision-support tool.
Category: General
118 Views
Annual-Meeting 5 months
Grandma Shout-Out: Very Grateful For Everything...Maybe Not All The Cooking
Grandma Shout-Out: Very Grateful For Everything...Maybe Not All The Cooking
Category: General
26 Views
Annual-Meeting 5 months
Questions About Larotrectinib: Who Should Be Tested, How Long Should They Be Treated, What Agent To Use
Questions About Larotrectinib: Who Should Be Tested, How Long Should They Be Treated, What Agent To Use
Category: General
48 Views
Annual-Meeting 5 months
Larotrectinib Efficacy & Safety In Pediatric TRK Fusion Cancer Patients: 94% Of The Children Treated With Larotrectinib Achieved A Response
Larotrectinib Efficacy & Safety In Pediatric TRK Fusion Cancer Patients: 94% Of The Children Treated With Larotrectinib Achieved A Response
Category: General
76 Views
Annual-Meeting 5 months
How To Identify Patients With An NTRK Gene Fusion: Will Require A Very Broad Genomic Sequencing
How To Identify Patients With An NTRK Gene Fusion: Will Require A Very Broad Genomic Sequencing
Category: General
301 Views
Annual-Meeting 5 months